Product Description
ANS-858 is an orally bioavailable, selective, reversible ALDH2 inhibitor. Currently, ANS-858 is in preclinical development. (Sourced from: https://amygns.com/product-pipeline/)
Mechanisms of Action: ALDH Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amygdala Neurosciences
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Alcohol-Related Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/02/2025 |
News Article |
Amygdala Neurosciences Selects ANS-858 for Clinical Development as a Novel ALDH2 Inhibitor for Substance Use Disorder |
|
05/14/2024 |
News Article |
ABMRF Invests in Amygdala Neurosciences to Develop ANS-858 for Alcohol Use Disorder |
|
08/01/2023 |
News Article |
Amygdala Neurosciences Awarded $2.0 million NIH Grant to Conduct IND Enabling Studies |